Novo Nordisk (NYSE: NVO) announced the headline results from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE